User menu

A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients.

Bibliographic reference Trakatelli, Myrto ; Toungouz, Michel ; Blocklet, Didier ; Dodoo, Ygierne ; Gordower, Laurence ; et. al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients.. In: Cancer Immunology, Immunotherapy : other biological response modifications, Vol. 55, no. 4, p. 469-474 (2006)
Permanent URL
  1. Banchereau J, Palucka AK, Dhodapkar M et al (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458
  2. Berzofsky JA, Terabe M, Oh S et al (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515–1525
  3. Blocklet D, Toungouz M, Kiss R et al (2003) 111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging 30:440–447
  4. Buelens C, Bartholome EJ, Amraoui Z et al (2002) Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 99:993–998
  5. Coulie PG, Karanikas V, Colau D et al (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98:10290–10295
  6. Cranmer LD, Trevor KT, Hersh EM (2004) Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53:275–306
  7. de Vries IJ, Krooshoop DJ, Scharenborg NM et al (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63:12–17
  8. Detournay O, Mazouz N, Goldman M, Toungouz M (2005) IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells. Hum Immunol 66:460–468
  9. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475–480
  10. Gjertson DW, Terasaki PI. HLA (1998) American Society for Histocompatibility and Immunogenetics, pp 190–191
  11. Godelaine D., Carrasco J., Lucas S., Karanikas V., Schuler-Thurner B., Coulie P. G., Schuler G., Boon T., Van Pel A., Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide, 10.4049/jimmunol.171.9.4893
  12. Guilloux Y, Lucas S, Brichard VG et al (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 183:1173–1183
  13. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357–2368
  14. Karanikas V., Lurquin C., Colau D., van Baren N., De Smet C., Lethe B., Connerotte T., Corbiere V., Demoitie M.-A., Lienard D., Dreno B., Velu T., Boon T., Coulie P. G., Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus, 10.4049/jimmunol.171.9.4898
  15. Lapenta C, Santini SM, Logozzi M et al (2003) Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 198:361–367
  16. Lonchay C, van der BP, Connerotte T et al (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101(suppl 2):14631–14638
  17. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al (2004) alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934–5937
  18. Mazouz N, Detournay O, Buelens C et al (2005) Immunostimulatory properties of human dendritic cells generated using IFN-beta associated either with IL-3 or GM-CSF. Cancer Immunol Immunother
  19. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56–58
  20. Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK (2004) Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 199:1503–1511
  21. Pardoll D, Allison J (2004) Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10:887–892
  22. Parlato S, Santini SM, Lapenta C et al (2001) Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98:3022–3029
  23. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036
  24. Renneson J, Salio M, Mazouz N, Goldman M, Marchant A, Cerundolo V (2005) Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells. Clin Exp Immunol 139:468–475
  25. Rouas R, Lewalle P, El Ouriaghli F, Nowak B, Duvillier H, Martiat P (2004) Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. Int Immunol 16:767–773
  26. Santini SM, Lapenta C, Logozzi M et al (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777–1788
  27. Thurner B, Haendle I, Roder C et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678
  28. Tosi D., Valenti R., Cova A., Sovena G., Huber V., Pilla L., Arienti F., Belardelli F., Parmiani G., Rivoltini L., Role of Cross-Talk between IFN- -Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens, 10.4049/jimmunol.172.9.5363